{"transactions":[{"id":2137186,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-14T16:06:52.000Z","date":"2022-10-14","kind":"disposition_to_issuer","acquired":false,"shares":118000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":8.2,"underlying":"Common Stock","underlying_shares":118000},"source":{"system":"sec-edgar","filing":"0000899243-22-033653","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924322033653/doc4.xml","form_type":"4"}},{"id":2137185,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Common Stock","published_at":"2022-10-14T16:06:52.000Z","date":"2022-10-14","kind":"other","acquired":false,"shares":79000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033653","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924322033653/doc4.xml","form_type":"4"}},{"id":2208678,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-12T16:24:46.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":118000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the stock option shall vest on July 11, 2023, and the remainder of the shares shall vest in equal monthly installments for a period of 36 months thereafter."}],"balance_after":118000,"derivative":{"exercise_price":8.2,"expiration_date":"2032-07-10","underlying":"Common Stock","underlying_shares":118000},"source":{"system":"sec-edgar","filing":"0000899243-22-025976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924322025976/doc4.xml","form_type":"4"}},{"id":2208677,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Common Stock","published_at":"2022-07-12T16:24:46.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":79000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock."}],"balance_after":79000,"source":{"system":"sec-edgar","filing":"0000899243-22-025976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924322025976/doc4.xml","form_type":"4"}},{"id":2549345,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:05:54.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":333,"price":26.0234,"value":8665.7922,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.795 to $26.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":453529,"source":{"system":"sec-edgar","filing":"0000899243-21-039356","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924321039356/doc4.xml","form_type":"4"}},{"id":2549344,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:05:54.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":2967,"price":25.4052,"value":75377.2284,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.78 to $25.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":453862,"source":{"system":"sec-edgar","filing":"0000899243-21-039356","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924321039356/doc4.xml","form_type":"4"}},{"id":2549343,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:05:54.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":4711,"price":24.2261,"value":114129.1571,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.78 to $24.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":456829,"source":{"system":"sec-edgar","filing":"0000899243-21-039356","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924321039356/doc4.xml","form_type":"4"}},{"id":2549342,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-05T21:05:54.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":10678,"price":23.2899,"value":248689.5522,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.78 to $23.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":461540,"source":{"system":"sec-edgar","filing":"0000899243-21-039356","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924321039356/doc4.xml","form_type":"4"}},{"id":2556775,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-29T16:15:21.000Z","date":"2021-09-28","kind":"sale","acquired":false,"shares":3750,"price":24.1153,"value":90432.375,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":472218,"source":{"system":"sec-edgar","filing":"0000899243-21-038191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924321038191/doc4.xml","form_type":"4"}},{"id":2564223,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-20T16:05:10.000Z","date":"2021-09-17","kind":"sale","acquired":false,"shares":2950,"price":24.0142,"value":70841.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":475968,"source":{"system":"sec-edgar","filing":"0000899243-21-036577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924321036577/doc4.xml","form_type":"4"}},{"id":2564222,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-20T16:05:10.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":800,"price":24.03,"value":19224.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":478918,"source":{"system":"sec-edgar","filing":"0000899243-21-036577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924321036577/doc4.xml","form_type":"4"}},{"id":2564221,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-20T16:05:10.000Z","date":"2021-07-02","kind":"sale","acquired":false,"shares":18586,"price":19.99,"value":371534.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."}],"balance_after":479718,"source":{"system":"sec-edgar","filing":"0000899243-21-036577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924321036577/doc4.xml","form_type":"4"}},{"id":2564220,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-20T16:05:10.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":18212,"price":23.89,"value":435084.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."}],"balance_after":498304,"source":{"system":"sec-edgar","filing":"0000899243-21-036577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924321036577/doc4.xml","form_type":"4"}},{"id":2773327,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-24T16:53:13.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":3750,"price":25.9716,"value":97393.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.52 to $26.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":516516,"source":{"system":"sec-edgar","filing":"0001209191-21-022860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000120919121022860/doc4.xml","form_type":"4"}},{"id":2879395,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-04T16:35:19.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":54849,"price":41.19,"value":2259230.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."}],"balance_after":520266,"source":{"system":"sec-edgar","filing":"0000899243-21-004953","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924321004953/doc4.xml","form_type":"4"}},{"id":2900953,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-21T19:28:36.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":81250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":81250,"derivative":{"exercise_price":42.15,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":81250},"source":{"system":"sec-edgar","filing":"0000899243-21-002767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924321002767/doc4.xml","form_type":"4"}},{"id":2900952,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-21T19:28:36.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":43750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":575115,"source":{"system":"sec-edgar","filing":"0000899243-21-002767","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924321002767/doc4.xml","form_type":"4"}},{"id":3072639,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":123076,"kind":"person","name":"Melian Agustin","position":1,"cik":"0001818064","reported_name":"Melian Agustin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-31T18:44:40.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":220700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on July 29, 2021, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":220700,"derivative":{"exercise_price":17,"expiration_date":"2030-07-29","underlying":"Common Stock","underlying_shares":220700},"source":{"system":"sec-edgar","filing":"0000899243-20-020933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818064/000089924320020933/doc4.xml","form_type":"4"}}]}